EX-99.2
Published on May 8, 2018
OPKO Health to Announce First Quarter 2018 Financial Results on May 8, 2018
MIAMI, May 2, 2018 OPKO Health, Inc. (NASDAQ:OPK) plans to announce its operating and financial results for the three months ended March 31, 2018 after the close of the U.S. financial markets on Tuesday, May 8, 2018.
OPKOs senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Tuesday, May 8, 2018.
Conference Call & Webcast Information
WHEN: Tuesday, May 8, 2018 at 4:30 p.m. Eastern time.
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 5976529
WEBCAST: http://investor.opko.com/events
For those unable to participate in the live conference call or webcast, a replay will be available beginning May 8, 2018 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 5976529. The replay can be accessed for a period of time on OPKOs website at http://investor.opko.com/events.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to establish industry leading positions
in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories,
the nations third largest clinical laboratory with a core genetic testing business and a
400-person sales and marketing team to drive growth and leverage new products, including the
4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical
business features RAYALDEE, an FDA-approved treatment for secondary hyperparathyroidism in stage 3
and 4 chronic kidney disease patients with vitamin D insufficiency (launched in November 2016),
OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a
clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists,
OPK88004, a SARM (Selective Androgen Receptor Modulator) for treating BPH (Benign Prostatic
Hypertrophy), OPK88002, a NK-1 antagonist to treat pruritus (itching) in dialysis patients, and
OPK88001, a proprietary oligonucleotide to treat Dravet Syndrome. In addition, the Company is
advancing its CTP technology, which includes a long acting hGH-CTP, a once weekly human growth
hormone injection (in phase 3 and partnered with Pfizer). OPKO also has production and distribution
assets worldwide, multiple strategic investments and an active business development strategy. More
information is available at www.opko.com.
CONTACTS
Company
OPKO Health, Inc.
David Malina, 305-575-4137
dmalina@opko.com
Director of Investor Relations
Investors
LHA Investor Relations
Miriam W. Miller, 212-838-3777
MMiller@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
# # #